Natural Killer Cell Therapies for Hematologic Malignancies

The "Natural Killer Cell and Lymphocyte-Targeted Immunotherapies in Cancer" study is an umbrella repository for data pertaining to multiple clinical trials that aim to assess NK cell and lymphocyte-targeted immunotherapy strategies across cancer types. Here, data from three trials, NCT03068819, NCT02782546, and NCT03687957 are presented.Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML after Allogeneic Hematopoietic Cell Transplant in Children and Adults (NCT03068819)Pediatric and young adult (YA) patients with acute myeloid leukemia (AML) who relapse after allogeneic hematopoietic cell transplantation (HCT) have extremely poor prognosis. Standard salvage chemotherapy and donor lymphocyte infusions (DLI) have little curative potential. Previous studies showed that... (for more see dbGaP study page.)

《癌症中自然杀伤细胞与淋巴细胞靶向免疫治疗》研究是一项伞状数据集库，收录了旨在覆盖多癌种、评估自然杀伤细胞（Natural Killer Cell，简称NK细胞）与淋巴细胞靶向免疫治疗策略的多项临床试验相关数据。本数据集库包含三项临床试验的相关数据，其编号分别为NCT03068819、NCT02782546及NCT03687957。

针对儿童与成人异基因造血干细胞移植后复发急性髓系白血病的细胞因子诱导记忆样NK细胞过继免疫治疗（NCT03068819）：
儿童及青年（YA）异基因造血干细胞移植（Allogeneic Hematopoietic Cell Transplant，简称HCT）后复发的急性髓系白血病（Acute Myeloid Leukemia，简称AML）患者预后极差。标准挽救性化疗与供者淋巴细胞输注（Donor Lymphocyte Infusions，简称DLI）几乎无治愈潜力。既往研究显示……（更多详情请参见dbGaP研究页面）